Pharming Group N.V.
corporate_fare Company Profile
Pharming Group N.V. (NASDAQ:PHAR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for PHAR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PHAR spans 6-K, 20-F.
Recent high-impact activity:
- Pharming Q3 Revenue Up 21% to $117.6M; Guidance Tightened to $380-390M
- Pharming Q3 Revenue Up 21% to $117.6M; Guidance Tightened, Operating Profit Jumps 89%
- Q3 Revenue Jumps 21% to $117.6M, Topping Consensus; Guidance Tightened
- Pharming Presents Positive Phase II Leniolisib Data in Genetic PIDs at ESID 2026
- Pharming CEO Fabrice Chouraqui Steps Down Immediately; Interim Co-CEOs Named
Financial Snapshot
Short Interest & Short Volume
1.47 days to coverFINRA reported short interest of 13,429 shares in PHAR as of the October 15, 2026 settlement, a 33.2% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On October 27, 2026, 37.0% of PHAR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
PHAR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.